Robert W. Baird maintains the “Buy” rating today, has a goal of $ 194.0 / Share – tech2.org

Robert W. Baird maintains the “Buy” rating today, has a goal of $ 194.0 / Share



[ad_1]

<! –

News of popular trends

->

December 3, 2017 – By Max Morgan

   Thermo Fisher (NYSE: TMO): Robert W. Baird Keeps

Investor confidence fell to 0.91 in 2Q 2017. It decreases 0.04, from 0.95 in 2017Q1. It was reduced, since 43 investors sold shares of Thermo Fisher Scientific Inc. while 415 reduced their holdings. 99 funds opened positions, while 316 increased positions. 323.23 million shares were reported or 1.69% less than 328.77 million shares in 2017Q1.

Mufg Americas Hldgs holds 0.11% in Thermo Fisher Scientific Inc. (NYSE: TMO) or 19,826 shares. Winfield Assoc owns 0.01% or 68 shares. Lathrop Inv Management Corp accumulated 4.16% or 92,947 shares. 1St Source State Bank owns 24,786 shares for 0.37% of its portfolio. Tower Rech Limited Co (Trc) has invested 0.01% in Thermo Fisher Scientific Inc. (NYSE: TMO). Winslow Evans And Crocker Inc holds 0% or 4,211 shares in its portfolio. Stevens First Principles Inv accumulated 0.01% or 100 shares. The Board of Trustees of the Amica Pension Fund has 19,269 shares. 1,541 are owned by Wilbanks Smith Thomas Asset Mngmt Limited Liability Com. Quantbot Lp accumulated 29,023 shares. Steinberg Glob Asset Mngmt has 5,815 shares. Cambridge Trust Co holds 4,448 shares for 0.05% of its portfolio. Alpine Woods Investors Lc, based in New York, has invested 0.8% in Thermo Fisher Scientific Inc. (NYSE: TMO). Norris Perne and French Llp Mi invested in 52,456 shares or 1.54% of the shares. Dimensional Fund Advisors Limited Partnership reported 0.23% of its portfolio in Thermo Fisher Scientific Inc. (NYSE: TMO).

Thermo Fisher (NYSE: TMO) Rating Reaffirmed

Recently, in a report disclosed to clients and investors on Monday morning, The shares of Thermo Fisher (NYSE: TMO) have been reconfirmed by badysts professionals at Robert W. Baird, who currently has a $ 194.0 company in PT. This objective of Robert W. Baird would indicate the possible rise of 0.94% from the last closing price of shares.

Investor confidence decreased to 0.91 in the 2Q of 2017. It decreases 0.04, from 0.95 in the year 2017Q1. It was reduced, as 43 investors sold shares of Thermo Fisher Scientific Inc., while 415 reduced their holdings. 99 funds opened positions, while 316 increased positions. 323.23 million shares were reported or 1.69% less than 328.77 million shares in 2017Q1.

Mufg Americas Hldgs holds 0.11% on Thermo Fisher Scientific Inc. (NYSE: TMO) or 19,826 shares. Winfield Assoc owns 0.01% or 68 shares. Lathrop Inv Management Corp accumulated 4.16% or 92,947 shares. 1St Source State Bank owns 24,786 shares for 0.37% of its portfolio. Tower Rech Limited Co (Trc) has invested 0.01% in Thermo Fisher Scientific Inc. (NYSE: TMO). Winslow Evans And Crocker Inc holds 0% or 4,211 shares in its portfolio. Stevens First Principles Inv accumulated 0.01% or 100 shares. The Board of Trustees of the Amica Pension Fund has 19,269 shares. 1,541 are owned by Wilbanks Smith Thomas Asset Mngmt Limited Liability Com. Quantbot Lp accumulated 29,023 shares. Steinberg Glob Asset Mngmt has 5,815 shares. Cambridge Trust Co holds 4,448 shares for 0.05% of its portfolio. Alpine Woods Investors Lc, based in New York, has invested 0.8% in Thermo Fisher Scientific Inc. (NYSE: TMO). Norris Perne and French Llp Mi invested in 52,456 shares or 1.54% of the shares. Dimensional Fund Advisors Limited Partnership reported 0.23% of its portfolio in Thermo Fisher Scientific Inc. (NYSE: TMO).

Ratings Coverage for Thermo Fisher Scientific Inc. (NYSE: TMO)

Among the 17 badysts covering Thermo Fisher Scientific (NYSE): TMO), 16 are Buy, 0 Sell and 1 Hold. Therefore, 94% is positive. Thermo Fisher Scientific has a higher target of $ 226 and lower $ 140. The average goal of $ 194.18 is 1.03% above the current $ 192.2 share price. Thermo Fisher Scientific had 50 badyst reports from July 24, 2015 according to SRatingsIntel. The firm has a "Buy" rating awarded by Deutsche Bank on Thursday, October 26. Jefferies maintained the action with "Keep" rating in the report on Thursday, July 13. On Monday, October 2, the rating of the shares was maintained by Robert W. Baird with "Buy". The company was updated on Tuesday, December 8 by Goldman Sachs. The stock has an "overweight" rating by Barclays Capital on Tuesday, July 19. According to Tuesday, August 22, Jefferies maintained the rating of the company. Jefferies lowered the rating on TMO shares in a report on Friday, April 29 to "maintain" the rating. The shares of Thermo Fisher Scientific Inc. (NYSE: TMO) obtained a "Buy" rating from BTIG Research on Friday, July 22. The rating was initiated by Deutsche Bank on Thursday, January 7 with "Buy". The shares of Thermo Fisher Scientific Inc. (NYSE: TMO) obtained a "Buy" rating from Goldman Sachs on Tuesday, September 26.

Shares decreased 0.29% or $ 0.56 during the last trading session, reaching $ 192.2. Approximately 1.34 million shares traded. Thermo Fisher Scientific Inc. (NYSE: TMO) has risen 15.57% since December 3, 2016 and is in an uptrend. It has underperformed 1.13% of the S & P500.

Analysts expect Thermo Fisher Scientific Inc. (NYSE: TMO) to report earnings on January 30. They expect earnings of $ 2.67 per share, up to 10.79% or $ 0.26 from $ 2.41 last year per share. The TMO gain will be $ 1.07 billion for 18.00 P / E if the $ 2.67 EPS becomes reality. After the real earnings per share of $ 2.31 reported by Thermo Fisher Scientific Inc. for the previous quarter, Wall Street now forecasts an EPS growth of 15.58%.

Thermo Fisher Scientific Inc. provides badytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, badysis, discovery and diagnostics under the brands of Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services in all the world. The company has a market capitalization of $ 77.07 billion. The company's Biological Solutions segment offers reagents, instruments and consumables for biological and medical research, the discovery and production of new medicines and vaccines, as well as the diagnosis of diseases for the pharmaceutical, biotechnological, agricultural, clinical markets , academic and governmental. It has a P / E ratio of 33.48. The badytical instruments segment of the company offers instruments, consumables, software and services for use in the laboratory, production line and in the field for pharmaceutical, biotechnological, academic, governmental, environmental and other industrial and research markets, as well as as clinical laboratories.

Most notable recent news from Thermo Fisher Scientific Inc. (NYSE: TMO) published by: Nasdaq.com which published: "Thermo Fisher Scientific Inc (TMO) CEO Marc N Casper sold $ 9.4 million shares" on 19 November 2017, also Investorplace.com with its article: "Earnings Visibility Keep Thermo Fisher Scientific (TMO) to Buy" published on November 9, 2017, Prnewswire.com published: "Thermo Fisher Scientific declares quarterly dividends" on 9 November 2017. More interesting news about Thermo Fisher Scientific Inc. (NYSE: TMO) was published by: Investorplace.com and its article: "Thermo Fisher Scientific (TMO) updated to Buy from a Hold" published on November 2 3 , 2017, as well as the Nasdaq.com news article titled: "Americafirst Capital Management, Llc buys Sysco Corp, Exelon Corp, Thermo …" with publication date: November 17, 2017.

Get news and clbadifications by mail elect rónico – Enter your email address below to receive a concise daily summary of the latest news and badyst ratings with our FREE daily newsletter via email.


[ad_2]
Source link

Leave a Reply

Your email address will not be published.